Neuren Pharmaceuticals Limited · ASX:NEU

Neuren Pharmaceuticals — Merger or Acquisition (July 2023)

8 slides from Neuren Pharmaceuticals's merger presentation, Jul 14, 2023

  1. Slide 1: Neuren and Acadia Expand Global Partnership for trofinetide (DAYBUE)

    For personal use only Neuren and Acadia Expand Global Partnership for trofinetide (DAYBUETM) 14 July 2023 IMPROVING THE LIVES OF PEOPLE WITH NEURODEVELOPMENTAL DISABILITIES Page□ 1

  2. Slide 2: Forward looking statements

    Forward looking statements This presentation contains forward looking statements that involve For personal use only risks and uncertainties. Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, Neuren can give no assurance that these expe

  3. Slide 3: Transaction to maximize value of trofinetide and NNZ-2591

    Transaction to maximize value of trofinetide and NNZ-2591 1 Expands Acadia’s exclusive trofinetide licence to worldwide, for up to additional US$527m to Neuren For personal use only (including US$100m up-front) plus mid-teens to low-20s % royalties on net sales outside North America 2 Leverages Acad

  4. Slide 4: Transaction economics to Neuren for trofinetide outside North America

    Transaction economics to Neuren for trofinetide outside North America US$100m upfront payment For personal use only US$35m following 1st commercial sale in Europe US$15m following 1st commercial sale in Japan Up to US$14m in relation to 1st commercial sale of a 2nd indication in Europe and Japan Tot

  5. Slide 5: Trofinetide North America Economics for Neuren unchanged

    Trofinetide North America Economics for Neuren unchanged Rett Syndrome Fragile X Syndrome  US$10m in 2022 following acceptance of NDA for review Up to in relation to development milestones For personal use only US$55m and 1st commercial sale in the US  US$40m following 1st commercial sale in the U

  6. Slide 6: Value of NNZ-2591 enhanced

    Value of NNZ-2591 enhanced Before Transaction Post Transaction For personal use only • Exclusive worldwide licence to Acadia for Rett Rett Rett Partnership and Fragile X syndromes only Global with Acadia • Potential future payments to Neuren for NNZ- restrictions Fragile X Fragile X 2591 in Rett and

  7. Slide 7: Transforming catalysts in 2023

    Transforming catalysts in 2023 Commercial ✓ DAYBUE for Rett syndrome approved by FDA For personal use only ✓ Priority Review Voucher awarded to Acadia ✓ First US commercial sale - US$40m milestone payment Trofinetide • Quarterly royalties on net sales NA • Priority Review Voucher value one third sha

  8. Slide 8: Contact

    For personal use only CONTACT Jon Pilcher, CEO jpilcher@neurenpharma.com +61 438 422 271 8

Neuren Pharmaceuticals — Merger or Acquisition (July 2023) on 6ix